Reason for Extending the Initiation of IV Alteplase (v2020B1)

Specifications Manual for Joint Commission National Quality Measures (v2020B1)

Posted: 3/30/2020

Print this page

Home » Reason for Extending the Initiation of IV Alteplase

Release Notes:
Data Element
Version 2020B1

Name:

Reason for Extending the Initiation of IV Alteplase

Collected For:

ASR-IP-1, ASR-OP-1, STK-4

Definition:

Reasons for extending the initiation of IV alteplase to 3 to 4.5 hours.

Documentation of treatment to lower blood pressure prior to IV alteplase initiation
Documentation of patient/family refusal of IV alteplase which was recanted/reversed prior to IV alteplase initiation
Documentation of cardiac arrest, respiratory arrest, cardiopulmonary resuscitation, defibrillation, or intubation in the emergency department prior to IV alteplase initiation
Other reasons for extending the initiation of IV alteplase to 3 to 4.5 hours documented by physician/APN/PA or pharmacist

Question:

Is there documentation on the day of or day after hospital arrival of a reason for extending the initiation of IV alteplase to 3 to 4.5 hours of Time Last Known Well?

Format:

Length:	1
Type:	Alphanumeric
Occurs:	1

Allowable Values:

Y (Yes) There is documentation on the day of or the day after hospital arrival of a reason for extending the initiation of IV alteplase to 3 to 4.5 hours of Time Last Known Well.

N (No) There is no documentation on the day of or day after hospital arrival of a reason for extending the initiation of IV alteplase to 3 to 4.5 hours of Time Last Known Well, OR unable to determine from the medical record documentation.

Notes for Abstraction:

Documentation of a reason for extending the initiation of IV alteplase to 3 to 4.5 hours must be done on the day of or the day after hospital arrival and must refer to the time period prior to IV alteplase initiation. It is not necessary to review documentation outside of this timeframe to answer this data element.
“Other” reasons for extending the initiation of IV alteplase therapy to 3 to 4.5 hours must be documented by a physician/APN/PA or pharmacist.
EXCEPTION:
Nursing documentation of a telemedicine/teleneurology reason for extending the initiation of IV alteplase therapy to 3 to 4.5 hours is acceptable.
The following are acceptable as stand-alone reasons for extending the initiation of IV alteplase – IV alteplase therapy linkage is not needed:
- Documentation of treatment to lower blood pressure, (e.g. nicardipine, hydralazine), prior to IV alteplase initiation
- Documentation of patient/family refusal of IV alteplase which was recanted/reversed prior to IV alteplase initiation
- Documentation of cardiac arrest, respiratory arrest, cardiopulmonary resuscitation, defibrillation, or intubation in the emergency department prior to IV alteplase initiation
If “other” reasons are not mentioned in the context of IV alteplase, do not make inferences (e.g., do not assume that IV alteplase was initiated in 3 to 4.5 hours because patient consent could not be obtained from family in 3 hours unless explicitly documented).
Examples:
- Documentation to initiate IV alteplase for worsening symptoms following documentation to not give tPA because symptoms resolved after hospital arrival, select “Yes.”
- NIHSS score of 1 on arrival. IV alteplase ordered 4 hours after hospital arrival, select “No.”
System reasons are not acceptable as “other” reasons, regardless of any linkage to IV alteplase:
- Equipment-related (e.g., CT not available, IV pump malfunction)
- Pharmacy-related (e.g., alteplase not available from pharmacy)
- Staff-related (e.g., unable to contact consulting MD)

Suggested Data Sources:

Consultation notes
Emergency department record
History and physical
Nursing notes
Progress notes
Physician orders
Medical transport records
Medication reconciliation form
Transfer Form

Additional Notes:

Guidelines for Abstraction:

Inclusion	Exclusion
Thrombolytic therapy t-PA	Delay in hospital arrival greater than 2 hours Delay in stroke diagnosis Hold IV alteplase without a documented reason No IV access

Specifications Manual for Joint Commission National Quality Measures (v2020B1)
Discharges 07-01-20 (3Q20) through 12-31-20 (4Q20)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.